Tenax Therapeutics (TENX)
(Delayed Data from NSDQ)
$3.77 USD
-0.01 (-0.26%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $3.77 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Tenax Therapeutics, Inc. [TENX]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3-Ready Assets to Address Different Types of Pulmonary Hypertension -Initiating Coverage
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Levosimendan?s Significant Market Potential Remains Underappreciated; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TNX-201 IMPROVE Phase 3 Trial in PAH on Track for 2H22; Reiterate Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Registration-Enabling Studies in the Queue for 2022; Reiterate Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Just Getting Stronger in the Field of Pulmonary Hypertension; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Published Results Provide Strong HELP for Advancing Levosimendan to Phase 3 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Expansion Includes Innovative Clinical Development Plan; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Acquisition of PHPM Expands Expertise and Presence in Pulmonary Hypertension; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage With a Buy Rating and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department